Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude de l'INBRX-106 et de l'INBRX-106 en association avec le pembrolizumab chez des sujets atteints de tumeurs solides localement avancées ou métastatiques (agoniste hexavalent OX40)

4 novembre 2026 mis à jour par: Inhibrx Biosciences, Inc

Une étude ouverte, multicentrique, première chez l'homme, à dose croissante, de phase 1 portant sur l'INBRX-106 et l'INBRX-106 en association avec le pembrolizumab chez des sujets atteints de tumeurs solides localement avancées ou métastatiques

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

340

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Busan, Corée du Sud
        • Pas encore de recrutement
        • Inje University College of Medicine
        • Chercheur principal:
          • IL-Hwan Kim, MD, PhD
      • Cheongju-si, Corée du Sud
        • Pas encore de recrutement
        • Chungbuk National University Hospital
        • Chercheur principal:
          • Ki-Hyeong Lee, MD
      • Gyeonggi-do, Corée du Sud
        • Recrutement
        • The Catholic University of Korea, St. Vincent's Hospital
        • Chercheur principal:
          • Byoung Yong Shim
      • Hwasun, Corée du Sud
        • Pas encore de recrutement
        • Chonnam National University Hwasun Hospital
        • Chercheur principal:
          • In-Jae Oh, MD, MS, PhD
      • Incheon, Corée du Sud
        • Pas encore de recrutement
        • Gachon University Gil Medical Center
        • Chercheur principal:
          • Eun Kyung Cho, PhD, M.S
      • Seongnam-si, Corée du Sud
        • Pas encore de recrutement
        • CHA Bundang Medical Center
        • Chercheur principal:
          • Yoon Beom Sang
      • Seoul, Corée du Sud
        • Recrutement
        • Asan Medical Center
        • Contact:
        • Chercheur principal:
          • Dae Ho Lee, MD
      • Seoul, Corée du Sud
        • Recrutement
        • Severance Hospital, Yonsei University Health System
        • Contact:
        • Chercheur principal:
          • Sun Mun Lim
      • Seoul, Corée du Sud
        • Recrutement
        • The Catholic University of Korea Seoul St. Mary's Hospital,
        • Chercheur principal:
          • SookHee Hong
        • Contact:
      • Seoul, Corée du Sud
        • Pas encore de recrutement
        • Korea University Anam Hospital
        • Chercheur principal:
          • Yoon Ji Choi, MD, MS, PhD
      • Seoul, Corée du Sud
        • Pas encore de recrutement
        • Hanyang University Seoul Hospital
        • Chercheur principal:
          • Myung- Ju Ahn, MD, PhD, MS
      • Seoul, Corée du Sud
        • Pas encore de recrutement
        • Korea University Guro Hospital
        • Chercheur principal:
          • Sung Yong Lee
        • Chercheur principal:
          • Sung Yong Lee, MD, MS, PhD
      • Suwon, Corée du Sud
        • Pas encore de recrutement
        • Ajou University Hospital
        • Chercheur principal:
          • Yong-Won Choi, MD
      • Singapore, Singapour
        • Complété
        • Curie Oncology
      • Singapore, Singapour
        • Complété
        • Icon Cancer Centre Farrer Park
      • Singapore, Singapour
        • Complété
        • Icon Cancer Centre Mount Alvernia
      • Changhua, Taïwan
        • Actif, ne recrute pas
        • Changhua Christian Hospital (CCH)
      • Kaohsiung City, Taïwan
        • Actif, ne recrute pas
        • E-Da Cancer Hospital
      • Kaohsiung City, Taïwan
        • Actif, ne recrute pas
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
      • Tainan, Taïwan
        • Actif, ne recrute pas
        • National Cheng Kung University Hospital
      • Taipei, Taïwan
        • Complété
        • Taipei Veterans General Hospital
    • California
      • Duarte, California, États-Unis, 91010
        • Actif, ne recrute pas
        • City of Hope
      • Glendale, California, États-Unis, 91204
      • La Jolla, California, États-Unis, 92037
        • Pas encore de recrutement
        • UC San Diego Health - Moores Cancer Center
        • Chercheur principal:
          • Lyudmila Bazhenova, MD
      • Los Angeles, California, États-Unis, 90027
        • Recrutement
        • California Research Institute
        • Chercheur principal:
          • Ghassan Al-Jazayrly, MD
        • Contact:
      • Los Angeles, California, États-Unis, 90069
      • Los Angeles, California, États-Unis, 90033
        • Pas encore de recrutement
        • University of Southern California Norris Comprehensive Cancer Center
        • Chercheur principal:
          • Jorge Nieva, MD
      • Murrieta, California, États-Unis, 92562
        • Recrutement
        • Valkyrie Clinical Trials
        • Chercheur principal:
          • David Berz, MD
        • Contact:
      • Santa Rosa, California, États-Unis, 95403
        • Recrutement
        • Providence Medical Foundation
        • Chercheur principal:
          • Ian Anderson, MD
        • Contact:
    • Colorado
      • Lakewood, Colorado, États-Unis, 80228
        • Pas encore de recrutement
        • Valkyrie Clinical Trials - Colorado
        • Chercheur principal:
          • Jason Henry, MD
    • Florida
      • Clermont, Florida, États-Unis, 34711
        • Recrutement
        • Clermont Oncology Center
        • Chercheur principal:
          • Gopal Kunta, MD
        • Contact:
      • Orange City, Florida, États-Unis, 32763
        • Recrutement
        • Mid Florida Hematology and Oncology Center
        • Chercheur principal:
          • Santosh Nair, MD
        • Contact:
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322
        • Actif, ne recrute pas
        • Winship Cancer Institute - Emory University
    • Illinois
      • Chicago, Illinois, États-Unis, 60612
        • Pas encore de recrutement
        • University of Illinois Cancer Center
        • Chercheur principal:
          • Frank Weinberg, MD, PhD
      • Chicago, Illinois, États-Unis, 60637
        • Actif, ne recrute pas
        • The University of Chicago Medical Center
    • Iowa
      • Iowa City, Iowa, États-Unis, 52242
        • Recrutement
        • University of Iowa
        • Chercheur principal:
          • Douglas Laux, MD
        • Contact:
    • Kentucky
      • Louisville, Kentucky, États-Unis, 40202
    • Michigan
      • Detroit, Michigan, États-Unis, 48202
        • Recrutement
        • Henry Ford Cancer Institute
        • Chercheur principal:
          • Amy Weise, MD
        • Contact:
      • Detroit, Michigan, États-Unis, 48201
        • Complété
        • Barbara Ann Karmanos Cancer Institute
      • Grand Rapids, Michigan, États-Unis, 49546
        • Actif, ne recrute pas
        • START Midwest
    • Minnesota
      • Saint Louis Park, Minnesota, États-Unis, 55426
        • Actif, ne recrute pas
        • HealthPartners Cancer Research Center
      • Saint Paul, Minnesota, États-Unis, 55101
        • Complété
        • HealthPartners Cancer Research Center (Regions Hospital)
    • Missouri
      • St Louis, Missouri, États-Unis, 63110
        • Pas encore de recrutement
        • Washington University in St. Louis School of Medicine
        • Chercheur principal:
          • Brett Herzog, MD, PhD
    • Montana
      • Billings, Montana, États-Unis, 59102
        • Complété
        • Intermountain Health Cancer Centers of Montana
    • Nebraska
      • Grand Island, Nebraska, États-Unis, 68803
        • Pas encore de recrutement
        • Nebraska Cancer Specialists - Grand Island
        • Chercheur principal:
          • Ralph Hauke, MD
      • Omaha, Nebraska, États-Unis, 68130
        • Recrutement
        • Nebraska Cancer Specialists
        • Chercheur principal:
          • Ralph Hauke, MD
        • Contact:
    • New Jersey
      • Camden, New Jersey, États-Unis, 08103
        • Pas encore de recrutement
        • MD Anderson Cancer Center at Cooper
        • Chercheur principal:
          • Polina Khrizman, MD
    • New York
      • The Bronx, New York, États-Unis, 10467
        • Actif, ne recrute pas
        • Montefiore Medical Center
    • Ohio
      • Cleveland, Ohio, États-Unis, 44195
        • Actif, ne recrute pas
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, États-Unis, 97213
        • Actif, ne recrute pas
        • Providence Portland Medical Center
    • Pennsylvania
      • Allentown, Pennsylvania, États-Unis, 18103
        • Pas encore de recrutement
        • Lehigh Valley Health Network
        • Chercheur principal:
          • Muhammad Rizvi, MD
    • Tennessee
      • Knoxville, Tennessee, États-Unis, 37923
        • Pas encore de recrutement
        • University of Tennessee Health Science Center
        • Chercheur principal:
          • Sean Jordan, MD
      • Nashville, Tennessee, États-Unis, 37204
        • Actif, ne recrute pas
        • Vanderbilt University School of Medicine
    • Texas
      • Dallas, Texas, États-Unis, 75230
        • Complété
        • Sarah Cannon Research Institute at Mary Crowley
      • El Paso, Texas, États-Unis, 79915
        • Complété
        • Renovatio Clinical - El Paso
      • San Antonio, Texas, États-Unis, 78229
        • Complété
        • NEXT Oncology
      • The Woodlands, Texas, États-Unis, 77380
        • Complété
        • Renovatio Clinical
      • Tyler, Texas, États-Unis, 75701
        • Recrutement
        • The University of Texas Health Science Center at Tyler
        • Contact:
        • Chercheur principal:
          • Erminia Massarelli, MD, PhD, MS
    • Virginia
      • Fairfax, Virginia, États-Unis, 22031
        • Complété
        • Virginia Cancer Specialists
    • Wisconsin
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Recrutement
        • Froedtert Hospital and the Medical College of Wisconsin
        • Chercheur principal:
          • Jonathan Thompson, MD
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Select Inclusion Criteria:

  • Males or females aged ≥18 years.
  • Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
  • Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
  • Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
  • For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
  • For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
  • For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
  • All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
  • PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
  • Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.

Select Exclusion Criteria:

  • Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
  • Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
  • Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
  • Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
  • Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
  • Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
  • Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
  • History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
  • Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
  • Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
  • Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
  • Major surgery within 4 weeks prior to enrollment on this trial.
  • Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
  • Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
  • Additional in- and exclusion criteria per protocol.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part 1 INBRX-106 Escalation (Not Recruiting)

INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Expérimental: Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)

INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA
Expérimental: Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)

Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA
Expérimental: Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)

Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA
Expérimental: Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)

Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)

Autres noms:
  • KEYTRUDA
Expérimental: Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)

Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA

pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)

Autres noms:
  • KEYTRUDA
Comparateur actif: Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)

Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Expérimental: Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)

Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

Expérimental: Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)

Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA
Expérimental: Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting

Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA
Expérimental: Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)

Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA

carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4.

pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.

Autres noms:
  • Alimta®
Expérimental: Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC

This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA

pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.

Autres noms:
  • Alimta®

cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Expérimental: Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC

This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA

carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4

Expérimental: Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC

This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA
Expérimental: Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC

Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Autres noms:
  • KEYTRUDA

carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4.

pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.

Autres noms:
  • Alimta®

cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Délai: ~2 years

Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

~2 years
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Délai: ~2 years

Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

~2 years
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
Délai: ~2 years

Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab

~2 years
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
Délai: ~2 years

The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1

~2 years
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
Délai: ~2 years

Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

~2 years
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
Délai: ~2 years

Major pathological response (mPR) and pathological complete response (cPR) criteria.

~2 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Area under the serum concentration time curve (AUC) of INBRX-106
Délai: ~2 years

Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Maximum observed serum concentration (Cmax) of INBRX-106
Délai: ~2 years

Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Trough observed serum concentration (Ctrough) of INBRX-106
Délai: ~2 years

Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Time to Cmax (Tmax) of INBRX-106
Délai: ~2 years

Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Immunogenicity of INBRX-106
Délai: ~2 years

Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Délai: ~2 years

Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).

~2 years
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Délai: ~2 years

Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

~2 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Directeur d'études: Clinical Lead, Inhibrx Biosciences, Inc

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 décembre 2019

Achèvement primaire (Estimé)

1 juillet 2033

Achèvement de l'étude (Estimé)

1 juillet 2033

Dates d'inscription aux études

Première soumission

11 décembre 2019

Première soumission répondant aux critères de contrôle qualité

11 décembre 2019

Première publication (Réel)

13 décembre 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • Ph 1 Ph 2 INBRX-106
  • KEYNOTE A99 and MK-3475-A99 (Autre identifiant: Merck Sharp & Dohme LLC)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner